Tanabe Seiyaku Company, Limited

Thomas J Lobl

Pina M Cardarelli

Shiu-Lan Chiang

Wolfgang Scholz

Nancy Delaet

Shiu-Lang Chiang

Gobi Nagarajan

The present invention describes cyclic peptide compounds which modulate integrin mediated adhesion. These compounds can inhibit both .beta..sub.1 and .beta..sub.2 mediated adhesion. The invention further relates to therapeutic uses for these compounds in the treatment of adhesion related pathologies.

Cyclic peptide inhibitors of .beta..sub.1 and .beta..sub.2

Cyclized integrin receptor antagonist compounds useful in modulating cell adhesion, including adhesion related to fibronectin, as well as leukocyte adhesion to endothelial cells, are disclosed. Methods for synthesizing, testing, formulating, and using the compounds as therapeutic agents are also disclosed.

Cyclic cell adhesion modulation compounds

Peptides and derivatives useful as antagonists to interleukin 6, and uses for the same, are disclosed.

Interleukin 6 antagonist peptides

Cyclized integrin receptor antagonist compounds useful in modulating cell adhesion to integrin receptors, including adhesion related to fibronectin and/or fibronectin receptors, are disclosed. Methods for synthesizing, testing, formulating, and using the compounds as therapeutic agents are also disclosed.

Growing community of inventors

Encinitas, CA, United States of America

Thomas J Lobl